GlassScriptPhysician profile
Natalie A Hyde
NPI 1649381435
$3,985.76
in general payments reported to CMS, 2019-2025
34 companies · $804 in 2025
The $804 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.34 · 2022: $416 · 2023: $1,172 · 2024: $1,572 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,548.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $649.47 | 2021-2025 | |
| Novo Nordisk INC | $500.09 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $387.36 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $307.51 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $185.49 | 2023-2024 | |
| Amgen INC. | $162.57 | 2023-2025 | Otezla, Repatha, Otezla |
| Dexcom, INC. | $148.26 | 2023-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Exact Sciences Corporation | $147.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $144.71 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.44 | 2022-2025 | Jardiance, Spiriva Respimat |
| Abbott Laboratories | $126.09 | 2024-2025 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.67 | 2022-2025 | |
| Lundbeck LLC | $106.27 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $94.50 | 2022-2023 | Myrbetriq, Veozah |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $85.02 | 2023-2025 | Belsomra, Steglatro, Capvaxive |
| Novartis Pharmaceuticals Corporation | $62.59 | 2022-2024 | |
| Seqirus USA INC | $56.96 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Renalytix Ai, INC. | $53.52 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Boston Scientific Corporation | $46.33 | 2024-2025 | Watchman Flx |
| Xeris Pharmaceuticals, INC. | $44.90 | 2022-2023 | Gvoke Hypopen |
| Insulet Corporation | $44.10 | 2025 | Omnipod |
| Corcept Therapeutics | $28.22 | 2025 | Korlym |
| Rgh Enterprises LLC | $26.93 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.74 | 2023 | Cuvitru |
| Idorsia Pharmaceuticals US INC | $22.84 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $22.80 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $19.44 | 2024 | Injectafer |
| Sunovion Pharmaceuticals INC. | $18.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.97 | 2022 | |
| Esperion Therapeutics, INC. | $17.88 | 2024 | Nexletol |
| Dynavax Technologies Corporation | $15.86 | 2024 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $14.53 | 2022 | |
| Sumitomo Pharma America, INC. | $13.72 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Hyde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.